Skip to main content

Advertisement

SpringerLink
Log in

Bracing for the biosimilar wave

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

A Corrigendum to this article was published on 31 March 2017

This article has been updated

The regulatory uncertainty around biosimilars in the United States is finally lifting, just months after the first biosimilar monoclonal antibody hit the US market.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 31 March 2017

    The article has been updated to indicate that Sandoz ran a confirmatory study in chronic plaque psoriasis of its etanercept biosimilar versus active comparator, rather than versus placebo

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Bracing for the biosimilar wave. Nat Rev Drug Discov 16, 152–154 (2017). https://doi.org/10.1038/nrd.2017.36

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2017.36

  • Springer Nature Limited

This article is cited by

Search

Navigation